{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
LENSAR, Inc. Hits New 52-Week Low at $5.98 Amidst Declining Performance
LENSAR, Inc. has reached a new 52-week low, trading at USD 5.98, reflecting a significant decline of 57.71% over the past year. The company, with a market capitalization of USD 123 million, faces financial challenges, including a negative book value and a high debt-to-equity ratio.
LENSAR, Inc. Hits New 52-Week Low at $6.55 Amid Market Struggles
LENSAR, Inc. has hit a new 52-week low, reflecting significant volatility in its stock performance over the past year. Despite a strong return on equity, the company struggles with negative financial metrics, including a high debt-to-equity ratio and rising raw material costs, indicating ongoing challenges in the market.
LENSAR, Inc. Stock Plummets to New 52-Week Low of $6.70
LENSAR, Inc., a microcap firm in the Pharmaceuticals & Biotechnology sector, has hit a new 52-week low, reflecting a challenging year with a significant performance decline. The company faces financial difficulties, including a negative book value and a poor EBIT to Interest ratio, despite a high return on equity.
LENSAR, Inc. Forms Death Cross, Signaling Potential Bearish Trend Ahead
LENSAR, Inc. has recently encountered a Death Cross, indicating a potential shift in market sentiment. While the stock has performed well over the past year, recent weekly and monthly declines suggest a slowdown. Investors are advised to monitor the stock closely amid mixed technical signals and potential volatility.
Is LENSAR, Inc. technically bullish or bearish?
As of September 12, 2025, LENSAR, Inc. shows a mildly bullish trend with mixed technical indicators, outperforming the S&P 500 significantly over the past year with a return of 195.24% compared to 17.14%.
Is LENSAR, Inc. overvalued or undervalued?
As of November 9, 2020, LENSAR, Inc. is considered "risky" due to negative valuation metrics and overvaluation compared to peers, despite a strong year-to-date return of 38.7%.
Is LENSAR, Inc. overvalued or undervalued?
As of November 9, 2020, LENSAR, Inc. is considered "risky" and overvalued due to negative financial metrics, including a Price to Book Value of -18.68 and a P/E ratio of -15.81, despite a strong 1-year stock return of 176.92%.
Is LENSAR, Inc. technically bullish or bearish?
As of June 11, 2025, LENSAR, Inc. exhibits a neutral technical stance with mixed signals, as weekly indicators are mildly bearish while monthly indicators show a bullish trend, indicating a lack of clear direction.
What does LENSAR, Inc. do?
LENSAR, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, reporting net sales of $14 million and a net loss of $27 million as of March 2025. It has a market cap of $146.31 million and key metrics indicating significant debt and negative price-to-book value.
How big is LENSAR, Inc.?
As of Jun 18, LENSAR, Inc. has a market capitalization of 146.31 million and reported net sales of 57.07 million with a net profit of -56.58 million over the latest four quarters.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
